Repligen (RGEN) Competitors

Repligen (NASDAQ:RGEN) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.

Does the MarketBeat Community favor RGEN or EXEL?

Exelixis received 174 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 68.09% of users gave Exelixis an outperform vote while only 68.03% of users gave Repligen an outperform vote.

Company	Underperform	Outperform
Repligen	Outperform Votes 400 68.03%	Underperform Votes 188 31.97%
Exelixis	Outperform Votes 574 68.09%	Underperform Votes 269 31.91%

Which has more volatility and risk, RGEN or EXEL?

Repligen has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Do insiders & institutionals believe in RGEN or EXEL?

97.6% of Repligen shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 1.2% of Repligen shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has preferable valuation and earnings, RGEN or EXEL?

Exelixis has higher revenue and earnings than Repligen. Exelixis is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$638.76M	13.74	$41.58M	$0.72	218.32
Exelixis	$1.83B	3.73	$207.76M	$0.64	35.19

Do analysts rate RGEN or EXEL?

Repligen currently has a consensus price target of $196.70, suggesting a potential upside of 25.25%. Exelixis has a consensus price target of $26.29, suggesting a potential upside of 17.71%. Given Repligen's stronger consensus rating and higher probable upside, equities analysts plainly believe Repligen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Exelixis	0 Sell rating(s)	6 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.60

Is RGEN or EXEL more profitable?

Exelixis has a net margin of 11.35% compared to Repligen's net margin of 6.51%. Exelixis' return on equity of 8.57% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.51%	5.00%	3.78%
Exelixis	11.35%	8.57%	6.81%

Does the media favor RGEN or EXEL?

In the previous week, Repligen had 4 more articles in the media than Exelixis. MarketBeat recorded 11 mentions for Repligen and 7 mentions for Exelixis. Repligen's average media sentiment score of 0.62 beat Exelixis' score of 0.55 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Repligen and Exelixis tied by winning 9 of the 18 factors compared between the two stocks.